Youdim, M. B. H.

Iron, brain ageing and neurodegenerative disorders

Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience

Neurological diseases and metabolismIron Metabolism and Disorders

Cited by 1,801

Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains

Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 1,383

Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases

Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 445

Brain iron pathways and their relevance to Parkinson's disease

Berg, D., Gerlach, M., Youdim, M. B. H., Double, K. L., Zecca, L., Riederer, P., & Becker, G. (2001) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 362

Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis

Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 313

Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-κB) activation and cell death by tea extracts in neuronal cultures11Abbreviations: BT, Black Tea; EMSA, Electromobility Shift Assay; EGCG, (-)-Epigallocatechin-3-gallate; GT, Green Tea; NB SH-SY5Y cells, Human neuroblastoma SH-SY5Y cells; 6-OHDA, 6-hydroxydopamine; IL, Interleukin; LDH, Lactate Dehydrogenase; MPTP, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-κB, nuclear factor-κB; OS, Oxidative Stress; PD, Parkinson’s Disease; ROS, Reactive Oxygen Species; SNPC, Substantia Nigra Pars Compacta; TBARS, thiobarbituric acid reactive substances.

Levites, Y., Youdim, M. B. H., Maor, G., & Mandel, S. (2002) · Biochemical Pharmacology

Tea Polyphenols and EffectsParkinson's Disease Mechanisms and Treatments

Cited by 291

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases

Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B. H., & Fridkin, M. (2005) · Bioorganic & Medicinal Chemistry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 278

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 246

Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28

YOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 233

Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 185

Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents

Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology

Alzheimer's disease research and treatmentsMedicinal Plants and Neuroprotection

Cited by 164

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

Mandel, S., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Brain Research Reviews

Parkinson's Disease Mechanisms and TreatmentsNeuroprotection in Cerebral Ischemia

Cited by 157

Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease1

Avramovich‐Tirosh, Y., Amit, T., Bar‐Am, O., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2007) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 130

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., & Zheng, H. (2005) · Mechanisms of Ageing and Development

Cholinesterase and Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments

Cited by 128

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S. (2008) · The FASEB Journal

Alzheimer's disease research and treatmentsIron Metabolism and Disorders

Cited by 126

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., & Zheng, H. (2004) · Journal of Neural Transmission

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 123

Influence of neuromelanin on oxidative pathways within the human substantia nigra

Double, K. L., Ben-Shachar, D., Youdim, M. B. H., Zecca, L., Riederer, P., & Gerlach, M. (2002) · Neurotoxicology and Teratology

Parkinson's Disease Mechanisms and Treatmentsmelanin and skin pigmentation

Cited by 102

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease

Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006) · Parkinson’s Disease and Related Disorders

Parkinson's Disease Mechanisms and TreatmentsCholinesterase and Neurodegenerative Diseases

Cited by 58

Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons

Zheng, H., Youdim, M. B. H., Weiner, L. M., & Fridkin, M. (2005) · Biochemical Pharmacology

Neuroprotection in Cerebral IschemiaParkinson's Disease Mechanisms and Treatments

Cited by 53

Iron deficiency alters discrete proteins in rat caudate nucleus and nucleus accumbens

Youdim, M. B. H., Sills, M. A., Heydorn, W. E., Creed, G. J., & Jacobowitz, D. M. (1986) · Journal of Neurochemistry

Iron Metabolism and DisordersTrace Elements in Health

Cited by 31